Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down - What's Next?

Key Points

• Genmab A/S's stock price fell significantly, opening at $272.30 after closing at $285.00, marking a drop of 4.5%.
• For the most recent quarter, Genmab reported earnings per share of $5.42, exceeding estimates, but revenue of $925 million fell short of expectations.
• Genmab develops therapies for cancer treatment, with products including DARZALEX for multiple myeloma and teprotumumab for thyroid eye disease.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) shares gapped down prior to trading on Thursday . The stock had previously closed at $285.00, but opened at $272.30. Genmab A/S shares last traded at $272.30, with a volume of 24 shares changing hands.

Genmab A/S Trading Up 4.7%

The stock has a fifty day simple moving average of $240.28 and a 200-day simple moving average of $215.98. The company has a market capitalization of $18.83 billion, a PE ratio of 14.31 and a beta of 0.90.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $5.42 earnings per share for the quarter, beating the consensus estimate of $3.99 by $1.43. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The business had revenue of $925.00 million during the quarter, compared to the consensus estimate of $949.06 million.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.